- XORTX Therapeutics is focused on developing therapies for **gout** and **autosomal dominant polycystic kidney disease (ADPKD)**.  **[1729214_2137893_1]** 
- The company estimates a conservative market opportunity of **CAD 700 million** for its gout product (XORLO/oxypurinol formulation) for allopurinol-intolerant patients and a **CAD 1 billion-CAD 1.5 billion** opportunity for its ADPKD program.  **[1729214_2137893_1]** **[1729214_2137893_2]** **[1729214_2137893_3]** 
- XORTX plans to file an Investigational New Drug (IND) application in the next quarter and aims to file a New Drug Application (NDA) for the gout indication within **12-14 months**, followed by an estimated **9-12 month** review period.  **[1729214_2137893_1]** **[1729214_2137893_2]** **[1729214_2137893_4]** 
- Patent protection for XRx-026 extends through **2034** for general patents and through **2041 and 2043** for formulation and use patents, covering both gout and ADPKD applications.  **[1729214_2137893_5]** 
- The company's current market capitalization is around **$4 million-$5 million**, and it anticipates significant value creation as it progresses towards NDA submission and approval, aiming for a transition to being revenue positive.  **[1729214_2137893_6]**

XORTX Therapeutics Provides Update on Drug Development and Market Opportunities

- XORTX Therapeutics is primarily focused on its gout program (XORLO™), which targets a **$700 million** market opportunity for allopurinol-intolerant patients.  **[1729214_2137763_1]** **[1729214_2137763_2]** 
- The company plans to file an Investigational New Drug (IND) application in the next quarter and aims to submit a New Drug Application (NDA) within **12 to 14 months**.  **[1729214_2137763_1]** **[1729214_2137763_2]** **[1729214_2137763_4]** 
- XORTX projects peak net sales of approximately **$700 million per year** for the gout program.  **[1729214_2137763_2]** **[1729214_2137763_4]** 
- A secondary program for autosomal dominant polycystic kidney disease (ADPKD) is estimated to have a market opportunity of **$1 billion to $1.5 billion**, though it is not the current priority.  **[1729214_2137763_1]** **[1729214_2137763_4]** **[1729214_2137763_6]** 
- The company's current market capitalization is **$4 million to $5 million U.S.**, with management anticipating significant value creation as it progresses towards NDA submission and approval.  **[1729214_2137763_6]**

XORTX Therapeutics (XRTX)